Current public sample · FDA and regulatory strategy

Five funded companies.
Every claim traceable.

This is the shape of an AwardCue brief: hard award facts, a bounded service-fit hypothesis, contact provenance, explicit cautions, and the official record.

Issued August 15, 2026Facts rechecked against the official NIH RePORTER API on August 17, 2026Direct contact details withheld on this public page
01

NIH / NICHD · SBIR Phase II

VENOVA TECHNOLOGIES, INC.

91fit

Development of a novel, non-hormonal female contraceptive device to submit IDE

$1,100,754July 29, 2026Cambridge, MA

Why this may matter

  • The official project title names an IDE submission target.
  • Device development may need FDA classification and submission planning.
  • Manufacturing or scale-up language may create quality and regulatory-readiness work.

Verify before outreach

Confirm the current product, intended use, pathway, and agency alignment before outreach.

Contact research status

Historical domain-matched business contact available; verify the current role.

Open official NIH record ↗
02

NIH / NEI · SBIR Phase II

OCULOGENEX

88fit

Developing a gene therapy-based solution for early intervention in age related macular degeneration (AMD) to prevent disease progression

$1,092,536August 4, 2026La Habra, CA

Why this may matter

  • The therapeutic scope may need preclinical, CMC, and agency-interaction planning.
  • The gene-therapy scope may create biologic development-pathway questions.
  • The project narrative identifies a planned or targeted IND pathway.

Verify before outreach

Confirm the current development stage and IND strategy. Old direct details were withheld.

Contact research status

Historical contact name only; direct email and phone withheld as stale.

Open official NIH record ↗
03

NIH / NIAID · SBIR Phase II

HELIXBIND, INC.

90fit

Direct-from-specimen characterization of bloodstream infections

$1,000,000August 6, 2026Boxborough, MA

Why this may matter

  • The diagnostic scope may need intended-use, analytical-validation, and FDA pathway planning.
  • The narrative describes future FDA-clearance or submission studies as a target.
  • Manufacturing or scale-up language may create quality and regulatory-readiness work.

Verify before outreach

Verify the current FDA route, development stage, timing, and contact role.

Contact research status

Historical domain-matched business contact available; verify the current role.

Open official NIH record ↗
04

NIH / NIAID · SBIR Phase II

OAK THERAPEUTICS, INC.

91fit

Novel antiretroviral therapy delivery platform for infants and young children: oral dispensable strips (ODS)

$899,010August 5, 2026Lawrence, KS

Why this may matter

  • The therapeutic scope may need preclinical, CMC, and agency-interaction planning.
  • The narrative identifies a planned or targeted ANDA pathway.
  • Manufacturing and delivery-platform scale-up may create regulatory-readiness work.

Verify before outreach

Confirm the present formulation, pathway, and agency alignment before outreach.

Contact research status

Historical company-domain business contact available; verify the current role.

Open official NIH record ↗
05

NIH / NIAID · SBIR Phase II

JAN BIOTECH, INC.

91fit

Sequence-based RNA Fluorescence Assay to Measure Latent HIV Reservoirs

$998,781August 4, 2026Ithaca, NY

Why this may matter

  • The assay scope may need intended-use, analytical-validation, and FDA pathway planning.
  • The narrative identifies a planned or targeted 510(k) pathway.
  • Manufacturing or scale-up language may create quality and regulatory-readiness work.

Verify before outreach

Confirm the current assay claims, pathway, timing, and contact role.

Contact research status

Historical company-domain business contact available; verify the current role.

Open official NIH record ↗

What the score does not mean

A funded project is a research signal—not proof of buyer intent.

Fit scores rank the evidence against a subscriber's filters. They do not claim a company is shopping for services. AwardCue fails closed on weak records, labels historical contacts, and expects every outreach decision to be reviewed by a person.

Your market, not this example

Get five current signals matched to the work you sell.

No card. No call required. Tell us your service, territory, and minimum award size.

Request my free sample ↗

See how the FDA regulatory lead service works